| Primary |
| Breast Cancer Metastatic |
23.7% |
| Breast Cancer |
22.5% |
| Pain |
7.4% |
| Product Used For Unknown Indication |
6.5% |
| Hypertension |
5.0% |
| Prophylaxis |
4.3% |
| Constipation |
3.6% |
| Her-2 Positive Breast Cancer |
3.6% |
| Anxiety |
3.1% |
| Nausea |
3.1% |
| Depression |
2.9% |
| Insomnia |
2.4% |
| Premedication |
2.2% |
| Hypersensitivity |
1.7% |
| Bone Pain |
1.4% |
| Diabetes Mellitus |
1.4% |
| Nasopharyngitis |
1.4% |
| Analgesic Therapy |
1.2% |
| Asthma |
1.2% |
| Gastric Cancer |
1.2% |
|
| Disease Progression |
20.5% |
| Death |
8.2% |
| Pneumonia |
6.8% |
| Thrombocytopenia |
6.8% |
| Interstitial Lung Disease |
5.5% |
| Gastroenteritis |
4.1% |
| General Physical Health Deterioration |
4.1% |
| Hepatic Enzyme Increased |
4.1% |
| Hepatotoxicity |
4.1% |
| Metastases To Liver |
4.1% |
| Pleural Effusion |
4.1% |
| Pulmonary Embolism |
4.1% |
| Septic Shock |
4.1% |
| Asthenia |
2.7% |
| Cardiac Failure |
2.7% |
| Epistaxis |
2.7% |
| Fatigue |
2.7% |
| Gastrointestinal Haemorrhage |
2.7% |
| Hepatic Failure |
2.7% |
| Metastases To Central Nervous System |
2.7% |
|
| Secondary |
| Breast Cancer |
36.2% |
| Breast Cancer Metastatic |
21.3% |
| Product Used For Unknown Indication |
16.4% |
| Pain |
4.8% |
| Metastases To Bone |
3.9% |
| Neoplasm Malignant |
2.9% |
| Increased Appetite |
2.4% |
| Neuropathy Peripheral |
2.4% |
| Bone Pain |
1.9% |
| Convulsion Prophylaxis |
1.0% |
| Nausea |
1.0% |
| Prophylaxis |
1.0% |
| Rash Pruritic |
1.0% |
| Thrombosis |
1.0% |
| Abdominal Pain |
0.5% |
| Back Pain |
0.5% |
| Contraception |
0.5% |
| Depression |
0.5% |
| Dry Eye |
0.5% |
| Empyema |
0.5% |
|
| Metastases To Meninges |
17.8% |
| Neuropathy Peripheral |
13.3% |
| Thrombocytopenia |
11.1% |
| Disease Progression |
6.7% |
| Sudden Death |
6.7% |
| Dermatomyositis |
4.4% |
| Fatigue |
4.4% |
| Tumour Marker Increased |
4.4% |
| Ulcer |
4.4% |
| Vaginal Haemorrhage |
4.4% |
| Anal Abscess |
2.2% |
| Bacteraemia |
2.2% |
| Blood Creatinine Increased |
2.2% |
| Cholecystitis |
2.2% |
| Diarrhoea |
2.2% |
| Disease Recurrence |
2.2% |
| General Physical Health Deterioration |
2.2% |
| Hepatic Enzyme Increased |
2.2% |
| Interstitial Lung Disease |
2.2% |
| Lung Infection |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
54.5% |
| Breast Cancer Metastatic |
27.3% |
| Her-2 Positive Breast Cancer |
9.1% |
| Pain |
9.1% |
|
| Metastases To Lung |
25.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
25.0% |
| Pathological Fracture |
25.0% |
| Upper Gastrointestinal Haemorrhage |
25.0% |
|
